KANADA

EQS-News: DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH

Retrieved on: 
Friday, May 3, 2024
DTC, OTCQB, Cancer, Growth, FMS, Therapy, Spacecraft, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Vancouver, BC, Canada, April 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH (“FMS”), a European corporate financing consulting firm, was commissioned by Defence to execute on a financing strategy for the Company.
  • “Defence’s successful technology development has advanced the Company to becoming a clinical stage oncology company.
  • To advance our growth, Defence secures a strong financial European based advisor experienced in the biotech field.

EQS-News: DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION

Retrieved on: 
Friday, May 3, 2024
Vaccination, DTC, Microsoft Exchange Server, Mouse, OTCQB, Animal, Male, Protein, Unfolded protein response, Female, Disturbance, Antigen presentation, Toxicity, Melanoma, Therapy, Cancer, Vaccine

The use of AccuTOX® to reprogram these MSCs relies mainly on the induction of protein aggregation.

Key Points: 
  • The use of AccuTOX® to reprogram these MSCs relies mainly on the induction of protein aggregation.
  • In addition, our team found that at specific doses, AccuTOX® forms protein aggregates when mixed with tumor lysate, a process that pushes MSCs to degrade these intracellular complexes resulting in potent antigen presentation."
  • The ARM-002TM vaccine is even more potent, as it actually requires 10x less protein.
  • These results will set the target indication for the Phase I trials, and it also shows how versatile and adaptable the ARM-002TM anti-cancer vaccine is.

EQS-News: ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION

Retrieved on: 
Wednesday, April 10, 2024
Microsoft Exchange Server, Therapy, DTC, ADC, OTCQB, Generation, Spacecraft, News, Defense, Rope

Bei Tests als therapeutisches Vakzin bei einem Melanom-Modell führte ARM-002TM in Kombination mit dem Immuncheckpoint-Inhibitor Anti-PD1 in 80 % der Fälle zu einer vollständigen Reaktion.

Key Points: 
  • Bei Tests als therapeutisches Vakzin bei einem Melanom-Modell führte ARM-002TM in Kombination mit dem Immuncheckpoint-Inhibitor Anti-PD1 in 80 % der Fälle zu einer vollständigen Reaktion.
  • Darüber hinaus können entwickelte Immunzellen zu einem lang anhaltenden immunologischen Gedächtnis führen, das Patienten vor späteren Krebsrückfällen schützen kann.
  • Defence hat sich dafür entschieden, seinen AccuTOX®-Leitkandidaten zu testen, um einen Krebsimpfstoff der zweiten Generation zu entwickeln, da dieser bei einer intratumoralen Verabreichung in geringeren Dosierungen nachweislich die Antigenpräsentation in Krebszellen verbessert.
  • Der Kern der Defence Therapeutics-Plattform besteht in der ACCUM®-Technologie, die einen präzisen Transport von Impfantigenen oder ADCs in intakter Form zu den Zielzellen ermöglicht.

EQS-News: North Peak's Upcoming Drill Program to Target Gold on Prospect Mountain North; Drilling Plans Close to Being Finalized and Weather Improving

Retrieved on: 
Wednesday, April 10, 2024
Technical report, Technical, Gold, National instrument, Weather, Prospect Mountain, Homestake Mining Company, Peak, Qualified person (European Union), NPR, Jet fuel

Eureka, Nevada--(Newsfile Corp. - April 9, 2024) - North Peak Resources Ltd. (TSXV: NPR) (the "Company" or "North Peak") is finalizing plans for its upcoming drilling campaign on its Prospect Mountain Property in Eureka, Nevada (the "Property" or "Prospect Mountain") which is expected to consist of up to 15,000 feet of R/C drilling with 20-30 holes targeting the gold zones on patented claims in the Wabash and Delaware/Madrid areas located in the northern portion of the Property ("Prospect Mountain North") (see Figure 1 below). Drilling at Prospect Mountain North will be at select areas around the former high-grade Williams, Wabash and Chicago gold mines, and the Wabash area which had 91 holes for 27,615 feet of vertical RC drilling completed in 1998/1999 when the gold price was much lower (see Figure 2 below). The campaign is also expected to include follow-up on a drill hole drilled by Homestake Mining that returned very promising gold assays; it is a lone hole located in the eastern portion of the Property with no other historic drilling activity nearby (see Figure 3 below).

Key Points: 
  • North Peak's Upcoming Drill Program to Target Gold on Prospect Mountain North; Drilling Plans Close to Being Finalized and Weather Improving
    The issuer is solely responsible for the content of this announcement.
  • Prospect Mountain contains both patented and unpatented land claims and hosts some 15-20 former underground gold mines close to surface as well as around 11 miles of underground tunnels.
  • Figure 1: Map view showing Prospect Mountain North and eastern part of Property referenced in press release.
  • To view an enhanced version of this graphic, please visit:
    Figure 2: North Area - Section view looking North.

EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE

Retrieved on: 
Wednesday, April 10, 2024
Antigen presentation, Neoplasm, Microsoft Exchange Server, DTC, Therapy, Vaccination, Melanoma, OTCQB, Antigen, Vaccine

When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.

Key Points: 
  • When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.
  • Compared to current anti-cancer strategies, vaccination can stimulate specific immune responses capable of potentially curing established tumors.
  • In addition, developed immune cells can lead to a long-lasting memory response capable of further protecting the patient from subsequent cancer relapses.
  • Although the ARMTM vaccine can effectively present antigens to responding T cells, the large amount of antigen preparation required to generate the cellular vaccine might represent challenges in the clinic.

EQS-News: North Peak Reports at Least 8 Zones up to 9.5% Zinc and 4.6% Lead on Its First Exploration Hole in Eureka, Nevada, Along with a New Gold Zone of 0.6 g/t Au over 3.1 Meters

Retrieved on: 
Wednesday, March 13, 2024
Diamond, Carbonate, Soil, WS01, PB, Property, Anomaly, WS02, Peak, 3D, Diamond mine, Zinc, Gold, North Peak, Shaft, Orientation, CRD, NPR

Calgary, Alberta--(Newsfile Corp. - February 12, 2024) - North Peak Resources Ltd. (TSXV: NPR) (the "Company" or "North Peak") reports that its 3,253-foot first exploration core hole (PM23-001) successfully drilled the conductive Mobile MT geophysical anomaly identified from summer 2023 surveys on its Prospect Mountain Property in Eureka, Nevada (the "Property" or "Prospect Mountain") (see the Company's October 27, 2023 press release).

Key Points: 
  • "This initial drill hole was positioned to enable us to target the MT anomaly identified from an operationally efficient location in winter," commented Mike Sutton, Director and Senior Geologist.
  • PM23-001 was successful in intersecting several zones of pyrite, sphalerite, galena +- chalcopyrite mineralization in the projected area of the MT geophysical anomaly.
  • These results from WS01 and WS02 are consistent with the localized gold and polymetallic intercepts found in PM23-001.
  • Towards the end of PM23-001 (west of the underground workings), marbelization of the dolomite is present and granitic dyke was intersected.

EQS-News: DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Retrieved on: 
Wednesday, March 13, 2024
Therapy, FDA, Patent, Bile, Spacecraft, Lung, GLP, Breast, Reactive oxygen species, Patient, Survival, Cell death, Melanoma, Pharmaceutical industry

DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Key Points: 
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    The issuer is solely responsible for the content of this announcement.
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no.
  • 11,890,350 (‘350) by the United States Patent and Trademark Office (USPTO), broadly covering its breakthrough AccuTOX® technology.
  • This patent marks the fourth granted US patent in Defence’s ever-growing patent portfolio, which currently incudes seven published patent families.

EQS-News: North Peak Announces Results of Dump Sampling Program on Prospect Mountain, Eureka, Nevada

Retrieved on: 
Monday, February 5, 2024
Diamond, ICP-MS, Gold, Geology, NPR, LIMS, News, Silver, Aqua regia, Qualified person (European Union), QA/QC, Soil, AAS, Fig, Lead, PB, ALS, Property, Diamond mine, National instrument, ISO/IEC, Mining

Calgary, Alberta--(Newsfile Corp. - January 31, 2024) - North Peak Resources Ltd. (TSXV: NPR) (the "Company" or "North Peak") announces results from the first phase of sampling of surface workings on its Prospect Mountain property in Eureka, Nevada (the "Property"). As part of a surface mapping project, some of the dumps, numerous surface shafts, adits and scrapes were assayed.

Key Points: 
  • North Peak Announces Results of Dump Sampling Program on Prospect Mountain, Eureka, Nevada
    The issuer is solely responsible for the content of this announcement.
  • Calgary, Alberta--(Newsfile Corp. - January 31, 2024) - North Peak Resources Ltd. (TSXV: NPR) (the "Company" or "North Peak") announces results from the first phase of sampling of surface workings on its Prospect Mountain property in Eureka, Nevada (the "Property").
  • Twelve samples returned grades > 5 g/t Au, and averaged 10.34 g/t Au, 200.8 g/t Ag, 0.20% Cu, 2.96% Pb, 1.30% Zn.
  • The Company's QA/QC program includes the regular insertion of blanks and standards into the sample shipments, as well as instructions for duplication.

EQS-News: North Peak Completes First Drill Hole at Diamond Mine on Prospect Mountain, Eureka; Downhole EM Survey Being Undertaken Shortly; Assay Results Pending

Retrieved on: 
Tuesday, January 30, 2024
Diamond, CRD, Orientation, Property, Silver, ALS, Laboratory, Diamond mine, Qualified person (European Union), Zinc, Water, Prospect Mountain, NPR, News, National instrument, Lead, Uranium mining

Calgary, Alberta--(Newsfile Corp. - January 19, 2024) - North Peak Resources Ltd. (TSXV: NPR) (the "Company" or "North Peak") reports that it has drilled its first deep core hole at Prospect Mountain (the "Property") and that a BHEM survey is being undertaken to identify potential locations for further wedge drilling. This first hole NPR23-01 in Phase 1 of North Peak's program was 3,250 feet in length and targeted the roughly 2 kilometre conductive anomaly, located directly beneath the old oxide gold, silver, lead and zinc historical stopes of the Diamond Mine, as a result of geophysical surveys the Company carried out in the summer of 2023 (see the Company's October 27, 2023 press release).

Key Points: 
  • North Peak Completes First Drill Hole at Diamond Mine on Prospect Mountain, Eureka; Downhole EM Survey Being Undertaken Shortly; Assay Results Pending
    The issuer is solely responsible for the content of this announcement.
  • The drill pad was located at an operational optimal location, at the portal entrance to the Diamond mine.
  • The metal casing was left in the hole to allow for potential wedge holes that would be drilled following the completion of a downhole geophysical BHEM survey.
  • Samples for this first core hole have been submitted to ALS Laboratories and North Peak is awaiting the completion of the full multi-element results and expects results in the next few weeks.

EQS-News: DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH

Retrieved on: 
Saturday, January 13, 2024
Patient, Therapy, Neoplasm, Biotechnology, Mouse, Cancer, DTC, OTCQB, FDA, Defense, Growth, Pharmaceutical industry

These results widen the scope of application for AccuTOX® in the treatment of solid cancer tumors.

Key Points: 
  • These results widen the scope of application for AccuTOX® in the treatment of solid cancer tumors.
  • Recent studies demonstrated that AccuTOX® has enhanced therapeutic properties and a broader application in cancer therapeutics as it has successfully killed more than a dozen different murine and human cancer cell lines.
  • When initially delivered intranasally, AccuTOX® had a great impact on blocking tumor growth of pre-established lung nodules in mice.
  • When delivered as a monotherapy, AccuTOX® inhibited the growth of lung nodules.